Hospital
Steward Trumbull Memorial Hospital, INC.
Steward Trumbull Memorial Hospital, INC. was paid $16.49M by Medicaid between Jan 2018 and Nov 2024, across 217 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoSTEWARD TRUMBULL MEMORIAL HOSPITAL, INC.
WARREN, OH 44483
WARREN, OH 44483
33aNPI1053844761assigned 04/10/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.49M
24GClaims460,664
24DCodes billed217
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#55 of 101
Median peer was paid$22.32M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOYLE, JOHN controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 63,763 | $1.97M | |
| 2019 | 69,790 | $2.37M | |
| 2020 | 49,741 | $2.36M | |
| 2021 | 50,393 | $2.12M | |
| 2022 | 50,033 | $1.99M | |
| 2023 | 107,751 | $3.52M | |
| 2024incomplete | 69,193 | $2.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 26,320 | 24,035 | $2.97M |
| 96361 | Intravenous infusion, hydration; each additional hour | 16% | 9,467 | 8,450 | $2.58M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 22,222 | 20,820 | $2.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 16,555 | 14,843 | $2.16M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.5% | 11,251 | 10,110 | $1.24M |
| 70450 | Computed tomography, head or brain; without contrast material | 6.3% | 4,577 | 4,103 | $1.03M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 1,914 | 1,682 | $458K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 2,054 | 1,773 | $313K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 5,304 | 4,422 | $300K |
| 80053 | Comprehensive metabolic panel | 1.5% | 31,654 | 28,134 | $245K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 950 | 847 | $238K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 1,664 | 1,454 | $171K |
205 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,093 | $160K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,024 | $144K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 472 | $118K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,284 | $116K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,237 | $101K |
| G0378 | Hospital observation service, per hour | <1% | 1,185 | $94K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 216 | $81K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 840 | $73K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 425 | $73K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 509 | $63K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,277 | $61K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 505 | $54K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 583 | $52K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,526 | $46K |
| 83605 | <1% | 8,884 | $43K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,283 | $42K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,338 | $42K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 153 | $39K |
| 84484 | <1% | 9,625 | $37K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 103 | $30K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 46 | $30K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 704 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,445 | $27K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,560 | $25K |
| 93971 | <1% | 349 | $25K | |
| 31231 | <1% | 179 | $25K | |
| 73562 | <1% | 699 | $24K | |
| 72100 | <1% | 631 | $24K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 172 | $23K |
| 36415 | Collection of venous blood by venipuncture | <1% | 45,097 | $23K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,062 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,009 | $22K |
| 93017 | <1% | 184 | $20K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 88 | $19K |
| 80061 | Lipid panel | <1% | 1,824 | $19K |
| 88304 | <1% | 657 | $19K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,533 | $19K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 194 | $19K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,019 | $19K |
| 71250 | <1% | 222 | $18K | |
| 70486 | <1% | 210 | $18K | |
| 76642 | <1% | 135 | $17K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 45 | $17K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 78 | $15K |
| 73030 | <1% | 518 | $15K | |
| 84439 | <1% | 1,230 | $15K | |
| 76536 | <1% | 139 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 797 | $14K |
| 73630 | <1% | 633 | $14K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 97 | $14K |
| 73130 | <1% | 583 | $14K | |
| 72131 | <1% | 258 | $14K | |
| 95811 | <1% | 25 | $13K | |
| 73610 | <1% | 473 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,782 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,734 | $10K |
| 71271 | <1% | 70 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,286 | $9K |
| 76830 | Ultrasound, transvaginal | <1% | 277 | $9K |
| 93970 | <1% | 73 | $7K | |
| 73502 | <1% | 271 | $7K | |
| 82553 | <1% | 664 | $7K | |
| 82607 | <1% | 532 | $6K | |
| 94060 | <1% | 42 | $6K | |
| 83735 | <1% | 4,231 | $6K | |
| 82570 | <1% | 599 | $6K | |
| 74018 | <1% | 179 | $5K | |
| 87040 | <1% | 987 | $5K | |
| 81001 | <1% | 10,829 | $5K | |
| 73110 | <1% | 174 | $5K | |
| 81003 | <1% | 9,794 | $5K | |
| 87631 | <1% | 35 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,862 | $5K |
| 86850 | <1% | 222 | $5K | |
| 86900 | <1% | 405 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,588 | $4K |
| 84100 | <1% | 698 | $4K | |
| 59025 | Fetal non-stress test | <1% | 42 | $4K |
| 76770 | <1% | 25 | $4K | |
| 85027 | <1% | 2,400 | $4K | |
| 85379 | <1% | 1,477 | $4K | |
| 82043 | <1% | 527 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 118 | $3K |
| 12001 | <1% | 17 | $3K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 596 | $3K |
| 82728 | <1% | 229 | $3K | |
| 94729 | <1% | 48 | $3K | |
| 80184 | <1% | 196 | $3K | |
| 85610 | <1% | 2,260 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,995 | $3K |
| 87081 | <1% | 836 | $2K | |
| 86140 | <1% | 337 | $2K | |
| 84702 | <1% | 350 | $2K | |
| 90715 | <1% | 176 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,396 | $2K |
| 83880 | <1% | 945 | $2K | |
| 81025 | <1% | 6,118 | $2K | |
| 80164 | <1% | 283 | $2K | |
| 97597 | <1% | 20 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 12 | $2K |
| 83690 | <1% | 4,828 | $2K | |
| 72050 | <1% | 40 | $2K | |
| 74019 | <1% | 43 | $2K | |
| 94726 | <1% | 26 | $2K | |
| 83540 | <1% | 228 | $2K | |
| 90686 | <1% | 219 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 236 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 236 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,007 | $1K |
| 84466 | <1% | 168 | $1K | |
| 85007 | <1% | 1,514 | $1K | |
| 85652 | <1% | 563 | $1K | |
| 80143 | <1% | 830 | $1K | |
| 82077 | <1% | 1,015 | $1K | |
| 90756 | <1% | 108 | $1K | |
| 82962 | <1% | 1,256 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,094 | $995.10 |
| 82550 | <1% | 1,513 | $990.88 | |
| 82746 | <1% | 141 | $979.15 | |
| 76775 | <1% | 14 | $879.17 | |
| 77065 | Tomosynthesis, mammo | <1% | 28 | $791.73 |
| 84703 | <1% | 1,553 | $787.42 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,011 | $717.55 |
| 87077 | <1% | 246 | $640.83 | |
| 88342 | <1% | 121 | $637.55 | |
| 80179 | <1% | 801 | $628.91 | |
| 85730 | <1% | 881 | $604.68 | |
| 87186 | <1% | 459 | $592.67 | |
| 11045 | <1% | 19 | $590.96 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 25 | $541.25 |
| 71101 | <1% | 18 | $485.81 | |
| 72128 | <1% | 30 | $465.35 | |
| 84145 | <1% | 292 | $464.87 | |
| 83970 | <1% | 14 | $450.30 | |
| 87070 | <1% | 324 | $432.11 | |
| 82150 | <1% | 785 | $373.49 | |
| 84146 | <1% | 76 | $358.82 | |
| 86901 | <1% | 405 | $356.12 | |
| 77066 | Tomosynthesis, mammo | <1% | 16 | $348.53 |
| 87340 | <1% | 18 | $333.05 | |
| 82805 | <1% | 23 | $305.12 | |
| 73590 | <1% | 16 | $300.11 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,317 | $299.58 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 698 | $271.68 |
| 83550 | <1% | 46 | $261.07 | |
| 90633 | <1% | 25 | $237.52 | |
| 87147 | <1% | 328 | $231.88 | |
| 96376 | <1% | 184 | $229.92 | |
| 87205 | <1% | 359 | $225.07 | |
| 86706 | <1% | 13 | $224.21 | |
| 86803 | <1% | 16 | $212.63 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,558 | $194.55 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,006 | $189.80 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 47 | $179.14 |
| 90651 | <1% | 16 | $141.50 | |
| 00731 | <1% | 27 | $138.73 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 35 | $128.33 |
| Q3014 | Telehealth originating site facility fee | <1% | 51 | $127.92 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,283 | $123.96 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 15 | $114.25 |
| 84550 | <1% | 28 | $92.85 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,987 | $89.65 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,687 | $78.90 |
| J3490 | Unclassified drugs | <1% | 51 | $61.54 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 159 | $59.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 555 | $58.21 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,321 | $56.68 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 232 | $41.41 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 475 | $40.95 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 336 | $40.92 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 118 | $40.14 |
| 87430 | <1% | 88 | $33.31 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 12 | $33.28 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 19 | $33.23 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,505 | $29.52 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 181 | $24.95 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 24 | $23.32 |
| 87807 | <1% | 125 | $19.64 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,678 | $19.28 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 45 | $16.69 |
| 87088 | <1% | 30 | $15.23 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 18 | $13.87 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 205 | $9.46 |
| 81002 | <1% | 389 | $8.84 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 49 | $7.58 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 41 | $6.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,729 | $5.86 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 283 | $5.28 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 66 | $4.65 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 52 | $3.44 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 931 | $3.27 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 300 | $2.80 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 48 | $2.42 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 27 | $0.06 |
| 90734 | <1% | 12 | $0.02 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 61 | $0.00 |
| 00811 | 0% | 92 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 41 | $0.00 |
| 87075 | 0% | 49 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 14 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 41 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 53 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 72 | $0.00 |
| 00813 | 0% | 12 | $0.00 | |
| C1769 | Guide wire | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOYLE, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Steward ST. Annes Hospital Corporation | Fall River, MA | $82.71M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $6.76M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $6.16M |
| Southwest General Hospital LP | San Antonio, TX | $5.84M |
| Steward Sharon Regional Health System, INC. | Sharon, PA | $5.84M |
| SHC Youngstown Ohio Laboratory Services Company LLC | Poland, OH | $3.41M |
| Steward Melbourne Hospital, INC. | Melbourne, FL | $3.35M |
| Steward Hillside Rehabilitation Hospital, INC. | Warren, OH | $2.74M |
| Steward Sebastian River Medical Center, INC. | Sebastian, FL | $2.16M |
| Steward Northside Medical Center, INC. | Youngstown, OH | $1.58M |
| Steward Rockledge Hospital, INC. | Rockledge, FL | $974K |
| Newberry County EMS | Newberry, SC | $758K |
| Steward Sharon Regional Health System, INC. | Mercer, PA | $181K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.